alexa Economic Evaluation of Omalizumab in the Treatment of Severe Allergic Asthma in Adult Patients in Greece: A Cost Effectiveness Analysis of Clinical Trial and Real-Life Data
ISSN 2472-1042

Pharmacoeconomics: Open Access
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Economic Evaluation of Omalizumab in the Treatment of Severe Allergic Asthma in Adult Patients in Greece: A Cost Effectiveness Analysis of Clinical Trial and Real-Life Data

Venkateshwarlu Sonathi1, Magdalini Hatzikou2*, Mary Geitona3, Mike Baldwin3, Elena Panitti2 and Nikolaos Siafakas4

1Novartis Health care private limited, Hyderabad, India

2Novartis Hellas SA, Greece, Social and Educational Policy Department, University of Peloponnese

3Novartis Pharmaceuticals UK Limited

4Medical School, University of Crete, Greece

*Corresponding Author:
Magdalini Hatzikou
Sr Health Economics Manager
Novartis Hellas SA
12th Klm National Road 1
Metamorfosis, 14451, Greece
Tel: 0030-2102897155 / 00306955460765
E-mail: [email protected]

Received date: September 08, 2015; Accepted date: November 24, 2015; Published date: November 30, 2015

Citation: Sonathi V, Hatzikou M, Geitona M, Baldwin M, Panitti E (2015) Economic Evaluation of Omalizumab in the Treatment of Severe Allergic Asthma in Adult Patients in Greece: A Cost Effectiveness Analysis of Clinical Trial and Real-Life Data. Pharmacoeconomics 1:103. doi: 10.4172/2472-1042.1000103

Copyright: © 2015 Sonathi V, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Background: Severe asthma is a major cause of morbidity and mortality around the world, associated with a heavy societal burden. The aim of this study was to evaluate the economic value of omalizumab in the treatment of adult patients with severe asthma in Greece, from a societal perspective, based on both data collected via a clinical trial and data from a prospective observational study with real-world evidence (RWE) using a simulation model.
Method: A Markov cohort model was developed in Microsoft Excel to compare the costs and outcomes of omalizumab plus standard therapy (ST) versus ST alone. The time horizon was that of a lifetime. Costs and health outcomes were discounted annually at 3.5%. A primary analysis was based on clinical data from the INNOVATE trial, and a secondary analysis, was based on recently published real-world evidence on effectiveness of omalizumab. Both direct and indirect costs were incorporated. Unit costs were taken from publically available sources, Productivity losses were calculated based on published data, while utility values were taken from the INNOVATE study. Deterministic and probabilistic sensitivity analyses were undertaken to test the robustness of the model results.
Results: The addition of omalizumab to ST led to an incremental cost of €27,888 and € 27,255 per QALY gained in the primary and secondary analyses, respectively. The model appeared to be most sensitive to changes in the time horizon and the age of retirement. The results of the probabilistic sensitivity analysis showed that the probability of omalizumab being cost effective was 58% and 84%, at a threshold of €30,000 and € 40,000 (willingness to pay for one QALY), respectively.
Conclusion: Omalizumab appears to be a cost-effective treatment option for patients with severe asthma compared to ST in Greece, and this result is confirmed both with trial and real-world data.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version